A novel anti-EFNA4 drug (PF-06647263) binds specifically to EFNA4-expressing cells and subsequently induces DNA cleavage and apoptosis/cell death in triple-negative breast and ovarian tumors (Damelin et al., 2015; Garrido-Laguna et al., 2019). The gene discussed is EFNA4; the disease is ovarian neoplasm.